Erratum (DOI:10.1016/j.juro.2009.01.012);Genetic Polymorphisms of Matrix Metalloproteinases: Susceptibility and Prognostic Implications for Prostate Cancer

Journal of Urology

Volumn 181, Issue 5, 2009, Pages 2320-2325

  dos Reis, Sabrina Thalita ^a   Pontes Jr , José ^a   Villanova, Fabiola Elizabeth ^a   Borra, Priscila Maria de Andrade ^a   Antunes, Alberto Azoubel ^a   Dall'oglio, Marcos Francisco ^a   Srougi, Miguel ^a   Leite, Katia Ramos Moreira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

gene expression; genetic; matrix metalloproteinases; polymorphisms; prostate; prostatic neoplasms

Indexed keywords

FLUORESCENT DYE; GELATINASE A; GELATINASE B; GENOMIC DNA; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE;

ADULT; AGED; ALLELE; ARTICLE; BRAZIL; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION;

EID: 64049104781     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.05.055     Document Type: Erratum

References (20)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer Statistics, 2008. CA cancer J Clin 58 (2008) 71
2. Partin A.W., Kattan M.W., Subong E.N., Walsh P.C., Wojno K.J., Oesterling J.E., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445
3. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 23 (1992) 273
4. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18 (2000) 1135
5. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827
6. Curran S., and Murray G.I. Matrix metalloproteinases in tumor invasion and metastasis. J Pathol 189 (1999) 300
7. Zinzindohoue F., Lecomte T., Ferraz J.M., Houllier A.M., Cugnene P.H., Berger A., et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 15 (2005) 594
8. Price S.J., Greaves D.R., and Watkins H. Identifcation of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of SP-1 in allele-specific transcriptional regulation. J Biol Chem 276 (2001) 7549
9. Yu C., Pan K., Xing D., Liang G., Tan W., Zhang L., and Lin D. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 62 (2002) 6430
10. Miao X., Yu C., Tan W., Xiong P., Liang G., Lu W., et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306 C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63 (2003) 3987
11. Zhang J., Jin X., Fang S., Wang R., Li Y., Wang N., et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 26 (2005) 1748
12. Allan J.A., Docherty A.J., Barker P.J., Huskisson N.S., Reynolds J.J., and Murphy G. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 309 (1995) 299
13. O'Farrell T.J., and Pourmotabbed T. Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase. J Biol Chem 275 (2000) 27964
14. Wright D.K., and Manos M.M. Sample Preparation From Paraffin-Embedded Tissues (1990), Academic Press, New York 153-158
15. Hu Z., Huo X., Lu D., Qian J., Zhou J., Chen Y., et al. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res 11 (2005) 5433
16. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 3 (2002) 409
17. Zhu Y., Spitz M.R., Lei L., Mills G.B., and Wu X. A Single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61 (2001) 7825
18. Sfar S., Saad H., Mosbah F., Gabbouj S., and Chouchane L. TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet 172 (2007) 38
19. Xu E., Lai M., Lv B., Xing X., Huang Q., and Xia X. A Single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Commun 324 (2004) 999
20. Lai H.C., Chu C.M., Lin Y.W., Chang C.C., Nieh S., Yu M.H., et al. Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol Oncol 96 (2005) 314